Stocktoria

REVELATION BIOSCIENCES, INC. REVB

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-10-08 · LEI

REVELATION BIOSCIENCES, INC. financials (annual)

Revenue
2019202020212022202320242025
Net income
-$3638 -$1.6M -$12.0M -$10.8M -$120254 -$15.0M -$8.9M 2019202020212022202320242025
Free cash flow
-$11.2M -$18.3M 2019202020212022202320242025

Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).

MetricFY2025FY2024FY2023FY2022FY2021FY2020FY2019
R&D expense$4.1M$3.5M$4.1M$5.4M$6.9M
Operating income-$9.1M-$8.0M-$8.7M-$10.9M-$12.0M
Interest expense$41,759
Income tax$0$0$0$0$0
Net income-$8.9M-$15.0M-$120,254-$10.8M-$12.0M-$1.6M-$3,638
EPS (diluted)$-23.95$-1052.16$-8.44$-149.20$-42.50
Operating cash flow-$8.3M-$18.3M-$7.3M-$11.2M-$11.1M-$216,664
Free cash flow-$18.3M-$11.2M
Cash & equivalents$10.7M$6.5M$12.0M$5.3M$1.3M$11,734
Total assets$11.6M$6.6M$12.2M$5.5M$2.0M$74.2M$22,671
Total liabilities$2.7M$1.9M$5.6M$4.5M$2.1M$6.3M$26,309
Shareholders' equity$8.9M$4.7M$6.6M$1.1M-$7.8M-$5.7M-$3,638

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.